NOVAVAX INC (NVAX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 239,240 | 666,655 | 84,512 | 415,484 |
| Research and development | 79,233 | 88,937 | 87,164 | 106,946 |
| Selling, general, and administrative | 43,612 | 48,090 | 70,747 | 101,298 |
| Cost of sales | 15,325 | 14,115 | 60,619 | 46,242 |
| Total expenses | 138,170 | 151,142 | 218,530 | 254,486 |
| Income from operations | 101,070 | 515,513 | -134,018 | 160,998 |
| Interest expense | 5,518 | 5,723 | 4,236 | 4,143 |
| Other income, net | 11,902 | 10,056 | 15,922 | 7,731 |
| Income before income tax expense | 107,454 | 519,846 | -122,332 | 164,586 |
| Income tax expense | 946 | 1,200 | -1,032 | 2,205 |
| Net income | 106,508 | 518,646 | -121,300 | 162,381 |
| Basic (in shares) | 162,019,000 | 161,049,000 | 160,049,000 | 148,379,000 |
| Basic (in usd per share) | 0.66 | 3.22 | -0.76 | 1.09 |
| Diluted (in shares) | 177,215,000 | 177,625,000 | 160,049,000 | 165,855,000 |
| Diluted (in usd per share) | 0.62 | 2.93 | -0.76 | 0.99 |